| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1785* | 2013 |
| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ... Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018 | 1143 | 2018 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 593 | 2020 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 505 | 2021 |
| Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Presented in part at the 42nd annual meeting of the American … G Del Poeta, A Venditti, MI Del Principe, L Maurillo, F Buccisano, ... Blood, The Journal of the American Society of Hematology 101 (6), 2125-2131, 2003 | 470 | 2003 |
| Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management R Stasi, ML Evangelista, E Stipa, F Buccisano, A Venditti, S Amadori Thrombosis and haemostasis 99 (01), 4-13, 2008 | 427 | 2008 |
| Clinical significance of CD38 expression in chronic lymphocytic leukemia G Del Poeta, L Maurillo, A Venditti, F Buccisano, AM Epiceno, G Capelli, ... Blood, The Journal of the American Society of Hematology 98 (9), 2633-2639, 2001 | 403 | 2001 |
| Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized … S Amadori, S Suciu, D Selleslag, F Aversa, G Gaidano, M Musso, ... Journal of Clinical Oncology 34 (9), 972-979, 2016 | 384 | 2016 |
| Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia F Buccisano, L Maurillo, MI Del Principe, G Del Poeta, G Sconocchia, ... Blood, The Journal of the American Society of Hematology 119 (2), 332-341, 2012 | 355 | 2012 |
| Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st Annual Meeting of the American Society … A Venditti, F Buccisano, G Del Poeta, L Maurillo, A Tamburini, C Cox, ... Blood, The Journal of the American Society of Hematology 96 (12), 3948-3952, 2000 | 354 | 2000 |
| Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia F Lo-Coco, G Cimino, M Breccia, NI Noguera, D Diverio, E Finolezzi, ... Blood 104 (7), 1995-1999, 2004 | 312 | 2004 |
| Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia MI Del Principe, G Del Poeta, F Buccisano, L Maurillo, A Venditti, ... Blood 108 (3), 853-861, 2006 | 242 | 2006 |
| High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial R Willemze, S Suciu, G Meloni, B Labar, JP Marie, CJM Halkes, P Muus, ... Journal of clinical oncology 32 (3), 219-228, 2014 | 200 | 2014 |
| GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia A Venditti, A Piciocchi, A Candoni, L Melillo, V Calafiore, R Cairoli, ... Blood, The Journal of the American Society of Hematology 134 (12), 935-945, 2019 | 199 | 2019 |
| Toward optimization of postremission therapy for residual disease–positive patients with acute myeloid leukemia L Maurillo, F Buccisano, MI Del Principe, G Del Poeta, A Spagnoli, ... Journal of clinical oncology 26 (30), 4944-4951, 2008 | 199 | 2008 |
| Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic … MT Voso, S Fenu, R Latagliata, F Buccisano, A Piciocchi, MA Aloe-Spiriti, ... Journal of Clinical Oncology 31 (21), 2671-2677, 2013 | 184 | 2013 |
| Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult … F Buccisano, L Maurillo, A Spagnoli, MI Del Principe, D Fraboni, ... Blood, The Journal of the American Society of Hematology 116 (13), 2295-2303, 2010 | 182 | 2010 |
| Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia G Del Poeta, R Stasi, G Aronica, A Venditti, MC Cox, A Bruno, ... | 174 | 1996 |
| The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia F Buccisano, L Maurillo, V Gattei, G Del Poeta, MI Del Principe, MC Cox, ... Leukemia 20 (10), 1783-1789, 2006 | 169 | 2006 |
| Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy … F Ferrara, G Barosi, A Venditti, E Angelucci, M Gobbi, F Pane, P Tosi, ... Leukemia 27 (5), 997-999, 2013 | 157 | 2013 |